Cytokine Signalling Forum
Discussing axSpA: Symptom duration impact on bimekizumab efficacy and therapeutic switching drivers
- Autor: Vários
- Narrador: Vários
- Editor: Podcast
- Duración: 0:33:29
- Mas informaciones
Informações:
Sinopsis
Join Dr Sofia Ramiro and Dr Atul Dheodhar as they discuss the top publications in the world of axSpA. This month, the conversation covered the impact of shorter versus longer symptom duration on the efficacy of bimekizumab and the factors associated with therapeutic switching in SpA.
